[go: up one dir, main page]

WO1990010652A1 - Method of treating viral infections using lfa-1 - Google Patents

Method of treating viral infections using lfa-1 Download PDF

Info

Publication number
WO1990010652A1
WO1990010652A1 PCT/US1990/001255 US9001255W WO9010652A1 WO 1990010652 A1 WO1990010652 A1 WO 1990010652A1 US 9001255 W US9001255 W US 9001255W WO 9010652 A1 WO9010652 A1 WO 9010652A1
Authority
WO
WIPO (PCT)
Prior art keywords
subunit
lfa
sequence
human
cells
Prior art date
Application number
PCT/US1990/001255
Other languages
French (fr)
Inventor
Timothy A. Springer
Takashi K. Kishimoto
Thomas Roberts
Original Assignee
Dana Farber Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute filed Critical Dana Farber Cancer Institute
Publication of WO1990010652A1 publication Critical patent/WO1990010652A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • This invention relates to cellular adhesion.
  • Cellular adhesion is a critical function for guiding migration and localization of cells, and for maintaining the integrity of the body.
  • Receptors for extracellular matrix components such as fibronectin, laminin, and vitronectin mediate cellular adhesion during morphogenesis and wound healing.
  • regulatory networks require intimate cell-cell interaction among lymphocytes and antigen- presenting accessory cells, and cell-mediated cytolysis involves direct contact between the effector cell and virally-infected or transformed target cells.
  • Leukocyte- endothelial interactions are important in leukocyte mobilization into inflammatory sites and in lymphocyte recirculation.
  • the invention features a) substantially pure recombinant 0-subunit of a human glycoprotein concerned with cellular adhesion, or b) a biologically active fraction of this u-subunit, c) an analog of the /J-subunit, or c) a fragment of the J-subunit, composed of at least 10% of a contiguous sequence of the J-subunit.
  • the invention also features a cDNA sequence encoding for the J-subunit; and a vector containing a DNA sequence encoding therefor.
  • recombinant subunit is meant the polypeptide product of recombinant DNA encoding the /3-subunit, i.e., the polypeptide expressed from DNA which is not in its naturally occurring location within a chromosome.
  • natural subunit is meant that subunit produced naturally in vivo from naturally occurring and located DNA.
  • analog is meant a polypeptide differing from the normal polypeptide by one or more amino acids, but having substantially the biological activity of the normal polypeptide.
  • the invention also features any monoclonal antibody (MAb) raised against the recombinant B- subunit, a biologically active fraction, an analog, or a fragment thereof composed of at least 10%, preferably at least 80%, of a contiguous sequence of the ⁇ -subunit of a human glycoprotein.
  • MAb monoclonal antibody
  • the cDNA sequence encoding the LFA-1 /5-subunit or a fragment thereof may be derived from any of the naturally occurring genes encoding it, or synthesized chemically. Variations in this sequence which do not alter the amino acid sequence of the resulting protein, or which do not significantly alter the biological activity of the protein, are also acceptable, and are within this invention.
  • the human glycoprotein is LFA-1, Mac-I or pl50.95.
  • the invention permits the diagnosis and treatment of a variety of human disease states.
  • Fig. I is the DNA coding sequence of the alpha-subunit of LFA-1, Mac-I and pl50.95. Potential N-glycosylation sites are marked with triangles.
  • Figure 2 is a comparison of the amino acid sequence predicted from the cDNA in Fig. 1, and the amino acid sequence derived from enzyme digests of the alpha-subunit of LFA-1. Ambiguous determinations of amino acids are bracketed.
  • the code for amino acids is as follows:
  • Trp Trp, w -tryptophan
  • the 0-subunit of any of the above described related glycoproteins is isolated by standard procedures and the amino acid sequence of at least a part of it determined. From this analysis a synthetic oligonucleotide probe, corresponding to the amino acid sequence, is synthesized and used as a probe for a genomic or cDNA library containing a DNA sequence encoding the /J-subunit. An example of this procedure is given below. One skilled in the art will realize that this represents only one of many methods which can be used to achieve cloning of the gene encoding the LFA-1 0-subunit.
  • the pl50.95 protein was purified from hairy cell leukemia spleens (Miller et al., 1986, 137 J. Immunol. 2891, hereby incorporated by reference); Mac-1 was purified from pooled human leukocytes (Miller et al., supra); and LFA-1 was purified from the SKW3 T cell line using TS1/22 monoclonal antibody (Sanchez-Madrid et al . 1983, J. Exp. Med. 158:586, hereby incorporated by reference).
  • SUBSTITUTESHEET the level of free radicals in the gel. Bands were visualized by soaking the gel for several minutes in 1 M KCI and then excised. The 0-subunit was electroeluted using the apparatus and method described by Hunkapillar et al., supra. The purified protein was reduced with 2 mM DTT in the presence of 2% SDS and alykylated with 5 mM iodoacetic acid in the dark. (In some cases, the protein was reduced and alkylated prior to running the preparative gel.)
  • the tryptic peptides were resolved by reverse phase HPLC (Beckman Instruments) with a 0.4 X 15 cm C4 column (Vydac, Hesperig, CA), and eluted from a 2 hr linear gradient from 0 to 60% acetonitrile. 0.1% TFA was included in both the aqueous and organic solvents. The peaks were monitored at 214 and 280 nm and collected into 1.5 ml polypropylene tubes. The fractions were concentrated to 30 ⁇ or less on a speed-vac apparatus, and selected peptides subjected to sequence analysis using a gas phase icrosequenator (Applied Biosyste s, Foster City, CA).
  • fl-subunit of pl50.95 pl50,95 was affinity purified from the spleens of human patients with hairy cell leukemia using a monoclonal antibody specific for the alpha subunit (MW approx. 150,000, Miller et al., su p ra ) .
  • Analysis of the purified protein by SDS-PAGE and silver staining revealed the characteristic alpha and beta
  • SUBSTITUTESHEET subunit with no significant amounts of contaminating proteins.
  • the /J-subunit band was excised from a preparative SDS-PAGE gel and electroeluted, as described above.
  • the N-terminus of the beta subunit was blocked and therefore could not be sequenced.
  • Internal amino acid sequence information was obtained by digesting the /J-subunit with trypsin. The tryptic peptides were resolved by reverse phase HPLC and eluted on a 60% acetonitrile gradient. Peaks analyzed by absorbance at 214 and 280 nm were collected and applied to a gas phase microsequenator.
  • the peptide sequences of two of these fragments is: P-61 Peptide Sequence: LeuTyrGluAsnAsnlleGlnProIlePheAlaValThrSer P-20 Peptide Sequence: ThrAspThrGlyTyrlleGlyLys.
  • oligonucleotide probes Two strategies were adopted for constructing oligonucleotide probes.
  • a unique sequence 39mer was designed from peptide P-61 based on human codon usage frequency (Lathe, 1985. J. Mol. Biol. 183:1). Its sequence is: 3'- GACATACTCTTGTTGTAGGTCGGGTAGAAACGACACTGG -5'.
  • two sets of mixed sequence probes were constructed such that every possible sequence was represented.
  • a 20mer of 96-fold redundancy was derived from peptide P-61, and a 17mer of 192- fold redundancy was constructed based on the sequence from a different peptide fragment of the J-subunit, P-20.
  • the 39mer and the mixed sequence 20mer were used to probe a Northern blot of poly A+selected RNA from PMA-activated U937 cell s.
  • SUBSTITUTE SHEET and C03 cells (Springer et al., 1984, J. Exp. Med. 160:1901, an EBV-transformed cell line from a healthy donor) were grown in RPMI 1640 containing 10-15% fetal calf serum in a - humidified atmosphere of 5% C0 2 and 37 ⁇ C.
  • the U937 cells were activated with 2 ng/ l PMA for three days prior to harvesting.
  • the cells were lysed in a 4M guanidinium isothiocyanate solution, and RNA isolated in a 5.7M CsCl gradient.
  • RNA was selected with oligo (dT)- cellulose columns (Maniatis et al., Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory, N.Y., 1982) or oligo (dT)-affinity paper (Amersham). This RNA was denatured and sized on a 1% agarose gel containing formaldehyde (Maniatis et al , supra) and transferred to nylon membranes (BioRad) in 20X SSC. A lane containing 28S and 18S ribosomal RNA from human cells or 23S and 16S rDNA from Escherichia coli was run to provide molecular weight standards.
  • the filters were hybridized with nick-translated probe DNA at 42°C for 18 hr in 5 x SSPE, 50%- formamide, 10% dextran sulfate, 1 X Denhardts, 0.5% SDS and 100 ug/ml denatured salmon sperm DNA, and washed at high stringency (65 ⁇ C) in 0.2X SSC and 0.1% SDS. Both probes identified a band of approximately 3 kb. The 39mer gave a much stronger signal and was chosen for the primary screening of a cDNA library.
  • a human tonsil cDNA library (gift of L. Vogelstein) was size-selected for inserts of 2kb or greater and constructed in ⁇ gtll (Wong et al., 1985, Proc. Nat. Acad. Sci . U.S.A. 82:7711).
  • the original library of 4 X 10 5 reco binants was amplified once, and 200,000 recombinants plated at a density of 7500 plaques/100mm plate.
  • the plaques were amplified in situ on duplicate nitrocellulose filters, as described by Woo (1979, Meth. Enzym. 68:389).
  • the oligonucleotide probes were labeled with 32p_Ajp using polynucleotide kinase.
  • the filters were prehybridized for at least 2 hr at 42 ⁇ C in 6 X SCC, 1 X Denhardts, 0.5% SDS, 0.05% phosphate buffer, and 100 ⁇ g/ml of salmon sperm DNA.
  • Hybridization with the 39mer was overnight at 42 ⁇ C in prehybridization solution containing 20 ⁇ g/ml tRNA.
  • the filters were washed at 53°C to 55 ⁇ C with 6 X SSC, 0.1% SDS, and 0.05% phosphate buffer.
  • the damp filters were covered with plastic wrap and exposed to film with an intensifying screen. Phage that gave positive signals on duplicate filters were plaque purified and rescreened with the 39mer at a higher wash temperature (60 ⁇ C) and with 20mer and 17mer mixed sequence probes. 15 positive clones were picked. Eight of the clones crossreacted with each other and gave positive signals with the 20mer mixed sequence probe and the independent 17mer mixed sequence probe. These clones were chosen for further analysis.
  • a 263 bp Pstl/EcoRI restriction fragment which hybridized to the 39mer was subcloned into Ml3 vector and sequenced by the Sanger dideoxy chain termination method as follows.
  • the amino acid sequence deduced from the DNA sequence is identical in 13 of 14 positions to the peptide sequence from which the 39mer probe was derived, including one amino acid which was not included in the design of the oligonucleotide.
  • the predicted amino acid sequence shows that this peptide is preceded by a lysine and followed by an arginine, as expected for a tryptic fragment.
  • the one mismatch may be due to normal polymorphism.
  • the unique sequence oligonucleotide was 87% homologous to the cDNA sequence, despite the one amino acid mismatch.
  • the cDNA clones were restriction ' mapped by single and double restriction digests and, after end-labeling, by partial restriction digests (Maniatis et al., supra). Compatible
  • SUBSTITUTESHEET restriction fragments were subcloned directly into Ml3 cloning vectors. Other fragments were first blunt ended with Klenow, T4 polymerase, or Mung Bean nuclease (Maniatis et al., supra) and ligated into the Hindi or Smal site of the M13 polylinker. The nucleotide sequence of both strands was determined by the dideoxy chain termination method of Sanger et al. (1977, Proc. Nat. Acad. Sci. U.S.A. 74:5463) using 35 S- dATP.
  • the first ATG is at position 73, and the sequence surrounding the ATG is consistent with the consensus rules for an initiation codon (Kozak 1984, Nucl . Acid. Res. 12:857).
  • This putative initiation codon is followed by an open reading frame of 2304 bp, which could encode a polypeptide of 769 amino acids (aa).
  • the stop codon ATC is followed by a 3' untranslated region of 394 bp.
  • the poly A tail was not found, although a consensus polyadenylation signal (AATAAA) is located 9 bp from the 3' end.
  • AATAAA consensus polyadenylation signal
  • the deduced amino acid sequence of the cDNA clones was compared to peptide sequence data from the beta subunit of Mac-1, LFA-1, and pl50,95 (Fig. 2).
  • one other peptide was sequenced from the beta subunit of pl50,95. Tryptic peptides were also prepared and analyzed from the beta subunit of purified Mac-1 and LFA-1. Each peptide sequence is found within the deduced amino acid sequence (Figs. 1 and 2). Thus, it can be concluded that the cDNA encodes the /J-subunit of human LFA-1.
  • the cDNA clones hybridize to a single RNA species of approximately 3.0 kb, which is the same message identified by the 39mer oligonucleotide. This message is present in PMA- activated U937 cells (LFA-1+, Mac-1+, pl50,95 + ), JY
  • SU BSTITUTESHEET lymphoblastoid cells LFA-1+, Mac-T, pl50,95 “
  • EBV- transformed cells from a normal donor (LFA-1 + , Mac-1 " , pl50,95 “ ), but is absent in HeLa cells (LFA-1 " Mac-1 " , p!50, 95”).
  • clone 18.1.1 lacks the poly A tail, it is close to the estimated size of the RNA message.
  • the first domain which begins with the putative initiation methionine and extends 22 amino acids, has the characteristics of a signal sequence. This putative signal sequence is followed by a charged glutamine, a residue which is often cyclized at the N-terminal position. This would be consistent with the N-terminal blockage of the ⁇ - subunit, if the signal sequence is cleaved during processing.
  • the cDNA encoding the /J-subunit of human LFA-1 can be used to produce recombinant /J-subunit in large amounts.
  • the beta-subunit-encoding cDNA can be excised from the ⁇ gtll clones and introduced into an expression vector (plas id, cosmid, phage or other type) to express the ⁇ - subunit in J coli. using standard techniques.
  • the clones may be inserted into other vectors, such as mammalian, insect, or yeast expression vectors, and used to produce recombinant /3-subunit in mammalian or yeast cells.
  • the subunits produced by the above methods can be readily purified and used as an immunogen to raise monoclonal antibodies to the subunits.
  • These antibodies can be labelled and used in standard immunoassays to monitor the level of LFA- 1, Mac-1, or pl50,95 in white blood cells, and in the serum or other body fluids of patients having medical disorders associated with too many or too few cells having on their surfaces LFA-1 or related proteins.
  • diseases e.g., AIDS, characterized by im unosuppression can be expected
  • S U BSTITUTESHEET to be accompanied' by abnormally low levels of such cells, which are instrumental in fighting infections, and such diseases can thus be monitored by monitoring levels of these proteins.
  • other disease states e.g., autoimmune disease, allograft rejection, and graft-versus-host disease
  • autoimmune disease can be expected to be characterized by abnormally high levels of such cells, and thus also can be monitored by monitoring levels of these proteins.
  • They can also be used to diagnose leukocyte adhesion deficiency, an inherited deficiency in the LFA-1, Mac-1, and pl50,95 glycoproteins.
  • Antibodies to the B- subunit can also be used to purify LFA-1 or related proteins by conventional im unoaffinity purification methods.
  • the purified proteins can also be used therapeutically.
  • the proteins can be administered to patients in need of such treatment in an effective amount (e.g., from 20-500 ⁇ g per kg body weight), and mixed with a pharmaceutically acceptable carrier substance such as saline.
  • Therapeutic utility of these proteins is based on the fact that disease states such as autoimmune diseases, allograft rejections, and graft-versus-host diseases involve abnormally high levels of cell-to-cell contact mediated by the recognition and binding of LFA-1 and related proteins to target antigen presenting cells, endothelial cells, and other types of cells.
  • LFA-1 or a related protein, or fragments thereof will compete for receptors for the cell-bound protein, inhibiting cell-to-cell binding and thus bringing about the desired immunosuppression.
  • a particular disease for which these proteins will be useful is the autoimmune disease rheumatoid arthritis.
  • administration is intravenous at about 20-500 ⁇ g per kg body weight, or directly at an inflamed joint of a patient suffering from rheumatoid arthritis.
  • oral administration or local application can be used by providing
  • the amount and method of administration will vary dependent upon the age and weight of the patient, and the disease to be treated.
  • Other autoimmune diseases which can be treated include systemic lupus erythematosis, juvenile onset diabetes, multiple sclerosis, allergic conditions, eczema, ulcerative colitis, inflammatory bowel disease, Crohn's disease, as well as allograft rejections (e.g., rejection of a transplanted kidney or heart).
  • LFA-1, Mac-1, and p!50,95 normally act in situ by binding to endothelial and other cells.
  • the free proteins or peptides, which are administered will be able to inhibit leukocyte immune responses and migration to inflammatory sites.
  • the ⁇ subunit cDNA clone can be used in prenatal diagnosis of leukocyte adhesion deficiency (LAD).
  • LAD disease is a deficiency in cell surface expression of LFA-1, Mac-1, and pl50,95 and is due at least in part to a primary genetic lesion in the ⁇ subunit.
  • Patients with the severe form of LAD disease suffer from recurrent bacterial infections and rarely survive beyond childhood.
  • the defect can be detected early in pregnancy since it is associated with a unique restriction fragment length polymorphism.
  • PstI digestion of human DNA and hybridization with the 1.8 kb EcoRI fragment (shown in Fig. 2) of the ⁇ subunit cDNA defines a restriction fragment length polymorphism (RFLP).
  • Diagnosis of this disease is therefore performed by standard procedure using the whole or a part of this EcoRI fragment.
  • the genomic DNAs of the parents of the fetus, and the fetus are screened with this probe and an analysis of their RFLPs made. In this way the probability that the fetus has the disease can be estimated.
  • ICAMs such as ICAM-1
  • ICAM-1 are recognized by certain human viruses (particularly rhinoviruses of the major type (which bind to ICAM-1). These viruses bind to human cells by virtue of this recognition, and thereby mediate viral infection.
  • SUBSTITUTESHEET Thus, a central step in the etiology of viral disease is the interaction between these cellular receptors and the virus.
  • Agents which suppress, compete with, or inhibit the ability of a virus to bind to an ICAM molecule thus have use in the treatment of viral (and particularly rhinoviral) infection.
  • One aspect of the present invention thus concerns the ability of the beta-subunit of human LFA-1, and its functional derivatives to interact with ICAM-1 and to thereby either prevent cell-viral attachment and viral infection, or to attenuate or diminish the severity or duration of such infection.
  • Such agents are preferably provided to a recipient patient as a heterodimer containing the molecule in association with a molecule of the ⁇ -subunit of a member of the CD-18 family (such as the ⁇ - subunits of LFA-1, pl50,95, or Mac-1).
  • the above-described goal of treating viral infection may be accomplished with a single agent or with a combination of more than one agents.
  • the above- described agent(s) of the present invention is to be provided to a recipient patient (for example, by intranasal means) at a dosage sufficient to permit the agent(s) to suppress, compete with, or inhibit the ability of a virus to bind to an ICAM molecule.
  • a dosage shall, in general, be (for each agent provided) from 0.01 pg/kg patient weight to 1 mg/kg patient weight, although greater or lesser amounts can be employed.
  • the administration of such agent(s) may be provided either “prophylactically” or “therapeutically.”
  • administration of such agent(s) may be provided either “prophylactically” or “therapeutically.”
  • the agent(s) are provided in advance of (i.e. prior to, at, or shortly after) the time of infection but in advance of any symptoms of viral infection.
  • the prophylactic administration of the agent(s) serves to prevent or attenuate any subsequent infection.
  • the agent(s) are provided at (or shortly after) the onset of a symptom of actual viral infection (such as, for example, the appearance of virally induced nasal congestion, etc. or the detection of virus in bodily fluids, or the detection of antibodies, directed against the virus, in the serum of an infected patient, etc).
  • the therapeutic administration of the agent(s) serves to attenuate any actual infection, and thus lessen its severity or duration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention features substantially pure recombinant β-subunit of a human glycoprotein concerned with cellular adhesion, or a biologically active fraction thereof, an analog thereof, or a fragment thereof composed of at least 10 % of a contiguous sequence of the β-subunit; a cDNA sequence encoding therefor; and a vector containing a DNA sequence encoding therefor. The invention also features any monoclonal antibody raised against the recombinant β-subunit of human LFA-1 and a method of treating rhinoviral infections using LFA-1.

Description

TITLE OF THE INVENTION:
"Method of Treating Viral Infections Using LFA-1"
This application is a continuation-in-part of U.S. Patent Application Serial No. 07/019,440; filed on February 26, 1987.
Background of the Invention
The work described herein was performed with the aid of government funding, and the government therefore has certain rights in the invention, specifically, the work was supported by N.I.H. grants 31798 and Al 05877.
This invention relates to cellular adhesion.
Cellular adhesion is a critical function for guiding migration and localization of cells, and for maintaining the integrity of the body. Receptors for extracellular matrix components such as fibronectin, laminin, and vitronectin mediate cellular adhesion during morphogenesis and wound healing. In the immune system, regulatory networks require intimate cell-cell interaction among lymphocytes and antigen- presenting accessory cells, and cell-mediated cytolysis involves direct contact between the effector cell and virally-infected or transformed target cells. Leukocyte- endothelial interactions are important in leukocyte mobilization into inflammatory sites and in lymphocyte recirculation. These cellular adhesion reactions are mediated in part by a family of structurally related glycoproteins, LFA-1, Mac-1, and pl50,95, all of which share a common β- subunit (hereinafter referred to as the ^-subunit of human LFA-1). Springer et al., 314 Nature 540, 1985; Springer et al., "The lymphocyte function-associated LFA-1, CD2, and LFA- 3 molecules: cell adhesion receptors of the immune system" Ann. Rev* Immunol. Vol. 5, 1987; both hereby incorporated by reference.
Summary of the Invention In general, the invention features a) substantially pure recombinant 0-subunit of a human glycoprotein concerned with cellular adhesion, or b) a biologically active fraction of this u-subunit, c) an analog of the /J-subunit, or c) a fragment of the J-subunit, composed of at least 10% of a contiguous sequence of the J-subunit. The invention also features a cDNA sequence encoding for the J-subunit; and a vector containing a DNA sequence encoding therefor. By recombinant subunit is meant the polypeptide product of recombinant DNA encoding the /3-subunit, i.e., the polypeptide expressed from DNA which is not in its naturally occurring location within a chromosome. By natural subunit is meant that subunit produced naturally in vivo from naturally occurring and located DNA. By analog is meant a polypeptide differing from the normal polypeptide by one or more amino acids, but having substantially the biological activity of the normal polypeptide. The invention also features any monoclonal antibody (MAb) raised against the recombinant B- subunit, a biologically active fraction, an analog, or a fragment thereof composed of at least 10%, preferably at least 80%, of a contiguous sequence of the ^-subunit of a human glycoprotein.
The cDNA sequence encoding the LFA-1 /5-subunit or a fragment thereof may be derived from any of the naturally occurring genes encoding it, or synthesized chemically. Variations in this sequence which do not alter the amino acid sequence of the resulting protein, or which do not significantly alter the biological activity of the protein, are also acceptable, and are within this invention.
Preferably the human glycoprotein is LFA-1, Mac-I or pl50.95.
As will be described in more detail below, the invention permits the diagnosis and treatment of a variety of human disease states.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof and from the claims.
Description of the Preferred Embodiments The drawings are first briefly described.
Drawings
Fig. I is the DNA coding sequence of the alpha-subunit of LFA-1, Mac-I and pl50.95. Potential N-glycosylation sites are marked with triangles.
Figure 2 is a comparison of the amino acid sequence predicted from the cDNA in Fig. 1, and the amino acid sequence derived from enzyme digests of the alpha-subunit of LFA-1. Ambiguous determinations of amino acids are bracketed. The code for amino acids is as follows:
Ala, A -alanine
Arg, R -arginine
Asn, N -asparagine
Asp. D -aspartic acid
Cys, C -cysteine
Gin, Q -glutamine
Glu, E -glutamic acid
Gly, G -glycine
His, H -histidine
He, I -isoleucine
Leu, L -leucine Lys, K -lysine
Met, M - ethionine (start)
Phe, F -phenylalanine
Pro, P -proline
Ser, S -serine
Thr, T -threonine
Trp, w -tryptophan
Tyr, Y -tryosine
Val, V -valine
Methods
In general, the 0-subunit of any of the above described related glycoproteins is isolated by standard procedures and the amino acid sequence of at least a part of it determined. From this analysis a synthetic oligonucleotide probe, corresponding to the amino acid sequence, is synthesized and used as a probe for a genomic or cDNA library containing a DNA sequence encoding the /J-subunit. An example of this procedure is given below. One skilled in the art will realize that this represents only one of many methods which can be used to achieve cloning of the gene encoding the LFA-1 0-subunit.
Purification of the U-Subunit
MAb's directed against the alpha subunits of pl50,95, Mac-1, and LFA-1, were used to affinity purify their respective proteins from three different sources. The pl50.95 protein was purified from hairy cell leukemia spleens (Miller et al., 1986, 137 J. Immunol. 2891, hereby incorporated by reference); Mac-1 was purified from pooled human leukocytes (Miller et al., supra); and LFA-1 was purified from the SKW3 T cell line using TS1/22 monoclonal antibody (Sanchez-Madrid et al . 1983, J. Exp. Med. 158:586, hereby incorporated by reference).
Preparative SDS-PAGE gels were run using the method of Laemmli (Hunkapiller et al., 1983, Meth. Enzym. 91:227). 0.1 mM Na Thioglycolate was added to the upper chamber to reduce
SUBSTITUTESHEET the level of free radicals in the gel. Bands were visualized by soaking the gel for several minutes in 1 M KCI and then excised. The 0-subunit was electroeluted using the apparatus and method described by Hunkapillar et al., supra. The purified protein was reduced with 2 mM DTT in the presence of 2% SDS and alykylated with 5 mM iodoacetic acid in the dark. (In some cases, the protein was reduced and alkylated prior to running the preparative gel.)
Amino acid seouencing
The above samples were precipitated using four volumes of ethanol at -20"C for 16 hr, and the protein pellet redissolved in 30-50 μl of 0.1 M NH4CO3 containing 0.1 M CaCl2 and 0.1% zwittergent 3-14 (Calbioche , San Diego, CA). The sample was then digested with 1% w/w trypsin for 6 hr at 37βC. At 2 and 4 hr during the incubation, additional trypsin (1% w/w) was added.
The tryptic peptides were resolved by reverse phase HPLC (Beckman Instruments) with a 0.4 X 15 cm C4 column (Vydac, Hesperig, CA), and eluted from a 2 hr linear gradient from 0 to 60% acetonitrile. 0.1% TFA was included in both the aqueous and organic solvents. The peaks were monitored at 214 and 280 nm and collected into 1.5 ml polypropylene tubes. The fractions were concentrated to 30 μ\ or less on a speed-vac apparatus, and selected peptides subjected to sequence analysis using a gas phase icrosequenator (Applied Biosyste s, Foster City, CA).
Example: fl-subunit of pl50.95 pl50,95 was affinity purified from the spleens of human patients with hairy cell leukemia using a monoclonal antibody specific for the alpha subunit (MW approx. 150,000, Miller et al., supra). Analysis of the purified protein by SDS-PAGE and silver staining revealed the characteristic alpha and beta
SUBSTITUTESHEET subunit, with no significant amounts of contaminating proteins. The /J-subunit band was excised from a preparative SDS-PAGE gel and electroeluted, as described above.
The N-terminus of the beta subunit was blocked and therefore could not be sequenced. Internal amino acid sequence information was obtained by digesting the /J-subunit with trypsin. The tryptic peptides were resolved by reverse phase HPLC and eluted on a 60% acetonitrile gradient. Peaks analyzed by absorbance at 214 and 280 nm were collected and applied to a gas phase microsequenator.
The peptide sequences of two of these fragments is: P-61 Peptide Sequence: LeuTyrGluAsnAsnlleGlnProIlePheAlaValThrSer P-20 Peptide Sequence: ThrAspThrGlyTyrlleGlyLys.
Two strategies were adopted for constructing oligonucleotide probes. A unique sequence 39mer was designed from peptide P-61 based on human codon usage frequency (Lathe, 1985. J. Mol. Biol. 183:1). Its sequence is: 3'- GACATACTCTTGTTGTAGGTCGGGTAGAAACGACACTGG -5'. In addition, two sets of mixed sequence probes were constructed such that every possible sequence was represented. A 20mer of 96-fold redundancy was derived from peptide P-61, and a 17mer of 192- fold redundancy was constructed based on the sequence from a different peptide fragment of the J-subunit, P-20. These sequences are given below.
20mer, Mixed Sequence 3'- ATACTATTATTATAAGTCCC -5'
G C G G C T G
17mer, Mixed Sequence 3'- CTATGACCAATATAACC -5'
G C C G G G G T T T
The 39mer and the mixed sequence 20mer were used to probe a Northern blot of poly A+selected RNA from PMA-activated U937 cell s. The U937 cel l s, J4 lymphobl astoid cell s, HeLa cel ls,
SUBSTITUTE SHEET and C03 cells (Springer et al., 1984, J. Exp. Med. 160:1901, an EBV-transformed cell line from a healthy donor) were grown in RPMI 1640 containing 10-15% fetal calf serum in a - humidified atmosphere of 5% C02 and 37βC. The U937 cells were activated with 2 ng/ l PMA for three days prior to harvesting. The cells were lysed in a 4M guanidinium isothiocyanate solution, and RNA isolated in a 5.7M CsCl gradient. Poly A+ mRNA was selected with oligo (dT)- cellulose columns (Maniatis et al., Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory, N.Y., 1982) or oligo (dT)-affinity paper (Amersham). This RNA was denatured and sized on a 1% agarose gel containing formaldehyde (Maniatis et al , supra) and transferred to nylon membranes (BioRad) in 20X SSC. A lane containing 28S and 18S ribosomal RNA from human cells or 23S and 16S rDNA from Escherichia coli was run to provide molecular weight standards.
The filters were hybridized with nick-translated probe DNA at 42°C for 18 hr in 5 x SSPE, 50%- formamide, 10% dextran sulfate, 1 X Denhardts, 0.5% SDS and 100 ug/ml denatured salmon sperm DNA, and washed at high stringency (65βC) in 0.2X SSC and 0.1% SDS. Both probes identified a band of approximately 3 kb. The 39mer gave a much stronger signal and was chosen for the primary screening of a cDNA library.
A human tonsil cDNA library (gift of L. Klickstein) was size-selected for inserts of 2kb or greater and constructed in λgtll (Wong et al., 1985, Proc. Nat. Acad. Sci . U.S.A. 82:7711). The original library of 4 X 105 reco binants was amplified once, and 200,000 recombinants plated at a density of 7500 plaques/100mm plate. The plaques were amplified in situ on duplicate nitrocellulose filters, as described by Woo (1979, Meth. Enzym. 68:389).
SUBSTITUTESHEET The oligonucleotide probes were labeled with 32p_Ajp using polynucleotide kinase. The filters were prehybridized for at least 2 hr at 42βC in 6 X SCC, 1 X Denhardts, 0.5% SDS, 0.05% phosphate buffer, and 100 μg/ml of salmon sperm DNA. Hybridization with the 39mer was overnight at 42βC in prehybridization solution containing 20 μg/ml tRNA. The filters were washed at 53°C to 55βC with 6 X SSC, 0.1% SDS, and 0.05% phosphate buffer. The damp filters were covered with plastic wrap and exposed to film with an intensifying screen. Phage that gave positive signals on duplicate filters were plaque purified and rescreened with the 39mer at a higher wash temperature (60βC) and with 20mer and 17mer mixed sequence probes. 15 positive clones were picked. Eight of the clones crossreacted with each other and gave positive signals with the 20mer mixed sequence probe and the independent 17mer mixed sequence probe. These clones were chosen for further analysis.
To confirm the identity of the cDNA clones, a 263 bp Pstl/EcoRI restriction fragment which hybridized to the 39mer was subcloned into Ml3 vector and sequenced by the Sanger dideoxy chain termination method as follows. The amino acid sequence deduced from the DNA sequence is identical in 13 of 14 positions to the peptide sequence from which the 39mer probe was derived, including one amino acid which was not included in the design of the oligonucleotide. Furthermore, the predicted amino acid sequence shows that this peptide is preceded by a lysine and followed by an arginine, as expected for a tryptic fragment. The one mismatch may be due to normal polymorphism. The unique sequence oligonucleotide was 87% homologous to the cDNA sequence, despite the one amino acid mismatch.
The cDNA clones were restriction' mapped by single and double restriction digests and, after end-labeling, by partial restriction digests (Maniatis et al., supra). Compatible
SUBSTITUTESHEET restriction fragments were subcloned directly into Ml3 cloning vectors. Other fragments were first blunt ended with Klenow, T4 polymerase, or Mung Bean nuclease (Maniatis et al., supra) and ligated into the Hindi or Smal site of the M13 polylinker. The nucleotide sequence of both strands was determined by the dideoxy chain termination method of Sanger et al. (1977, Proc. Nat. Acad. Sci. U.S.A. 74:5463) using 35S- dATP.
The complete nucleotide sequence and deduced amino acid sequence of the /J-subunit gene in the longest clone, 18.1.1 (2.8 kb is length), is shown in Figure 1. The first ATG is at position 73, and the sequence surrounding the ATG is consistent with the consensus rules for an initiation codon (Kozak 1984, Nucl . Acid. Res. 12:857). This putative initiation codon is followed by an open reading frame of 2304 bp, which could encode a polypeptide of 769 amino acids (aa). The stop codon ATC is followed by a 3' untranslated region of 394 bp. The poly A tail was not found, although a consensus polyadenylation signal (AATAAA) is located 9 bp from the 3' end.
The deduced amino acid sequence of the cDNA clones was compared to peptide sequence data from the beta subunit of Mac-1, LFA-1, and pl50,95 (Fig. 2). In addition to the P61 and P-20 peptide sequences given above, one other peptide was sequenced from the beta subunit of pl50,95. Tryptic peptides were also prepared and analyzed from the beta subunit of purified Mac-1 and LFA-1. Each peptide sequence is found within the deduced amino acid sequence (Figs. 1 and 2). Thus, it can be concluded that the cDNA encodes the /J-subunit of human LFA-1.
The cDNA clones hybridize to a single RNA species of approximately 3.0 kb, which is the same message identified by the 39mer oligonucleotide. This message is present in PMA- activated U937 cells (LFA-1+, Mac-1+, pl50,95+), JY
SUBSTITUTESHEET lymphoblastoid cells (LFA-1+, Mac-T, pl50,95"), and EBV- transformed cells from a normal donor (LFA-1+, Mac-1", pl50,95"), but is absent in HeLa cells (LFA-1" Mac-1", p!50, 95"). Although clone 18.1.1 lacks the poly A tail, it is close to the estimated size of the RNA message.
Within the deduced polypeptide are two regions of sufficient length and hydrophobicity that could span the membrane bilayer. The first domain, which begins with the putative initiation methionine and extends 22 amino acids, has the characteristics of a signal sequence. This putative signal sequence is followed by a charged glutamine, a residue which is often cyclized at the N-terminal position. This would be consistent with the N-terminal blockage of the β- subunit, if the signal sequence is cleaved during processing.
Use
The cDNA encoding the /J-subunit of human LFA-1 can be used to produce recombinant /J-subunit in large amounts. For example, the beta-subunit-encoding cDNA can be excised from the λgtll clones and introduced into an expression vector (plas id, cosmid, phage or other type) to express the β- subunit in J coli. using standard techniques. Alternatively the clones may be inserted into other vectors, such as mammalian, insect, or yeast expression vectors, and used to produce recombinant /3-subunit in mammalian or yeast cells.
The subunits produced by the above methods can be readily purified and used as an immunogen to raise monoclonal antibodies to the subunits. These antibodies can be labelled and used in standard immunoassays to monitor the level of LFA- 1, Mac-1, or pl50,95 in white blood cells, and in the serum or other body fluids of patients having medical disorders associated with too many or too few cells having on their surfaces LFA-1 or related proteins. For example, diseases, e.g., AIDS, characterized by im unosuppression can be expected
SUBSTITUTESHEET to be accompanied' by abnormally low levels of such cells, which are instrumental in fighting infections, and such diseases can thus be monitored by monitoring levels of these proteins. Also, other disease states, e.g., autoimmune disease, allograft rejection, and graft-versus-host disease, can be expected to be characterized by abnormally high levels of such cells, and thus also can be monitored by monitoring levels of these proteins. They can also be used to diagnose leukocyte adhesion deficiency, an inherited deficiency in the LFA-1, Mac-1, and pl50,95 glycoproteins. Antibodies to the B- subunit can also be used to purify LFA-1 or related proteins by conventional im unoaffinity purification methods.
The purified proteins, particularly LFA-1, Mac-1 and/or pl50,95, whether native or recombinant, can also be used therapeutically. The proteins can be administered to patients in need of such treatment in an effective amount (e.g., from 20-500 μg per kg body weight), and mixed with a pharmaceutically acceptable carrier substance such as saline. Therapeutic utility of these proteins is based on the fact that disease states such as autoimmune diseases, allograft rejections, and graft-versus-host diseases involve abnormally high levels of cell-to-cell contact mediated by the recognition and binding of LFA-1 and related proteins to target antigen presenting cells, endothelial cells, and other types of cells. The administration of LFA-1 or a related protein, or fragments thereof, will compete for receptors for the cell-bound protein, inhibiting cell-to-cell binding and thus bringing about the desired immunosuppression. A particular disease for which these proteins will be useful is the autoimmune disease rheumatoid arthritis. Preferably administration is intravenous at about 20-500 μg per kg body weight, or directly at an inflamed joint of a patient suffering from rheumatoid arthritis. Alternatively, oral administration or local application can be used by providing
SUBSTITUTE SHEET tablets, capsules, or solutions, or by applying lotions as required. The amount and method of administration will vary dependent upon the age and weight of the patient, and the disease to be treated. Other autoimmune diseases which can be treated include systemic lupus erythematosis, juvenile onset diabetes, multiple sclerosis, allergic conditions, eczema, ulcerative colitis, inflammatory bowel disease, Crohn's disease, as well as allograft rejections (e.g., rejection of a transplanted kidney or heart). LFA-1, Mac-1, and p!50,95 normally act in situ by binding to endothelial and other cells. Thus, the free proteins or peptides, which are administered, will be able to inhibit leukocyte immune responses and migration to inflammatory sites.
The β subunit cDNA clone can be used in prenatal diagnosis of leukocyte adhesion deficiency (LAD). LAD disease is a deficiency in cell surface expression of LFA-1, Mac-1, and pl50,95 and is due at least in part to a primary genetic lesion in the β subunit. Patients with the severe form of LAD disease suffer from recurrent bacterial infections and rarely survive beyond childhood. The defect can be detected early in pregnancy since it is associated with a unique restriction fragment length polymorphism. PstI digestion of human DNA and hybridization with the 1.8 kb EcoRI fragment (shown in Fig. 2) of the β subunit cDNA defines a restriction fragment length polymorphism (RFLP). Diagnosis of this disease is therefore performed by standard procedure using the whole or a part of this EcoRI fragment. The genomic DNAs of the parents of the fetus, and the fetus are screened with this probe and an analysis of their RFLPs made. In this way the probability that the fetus has the disease can be estimated.
ICAMs (such as ICAM-1) are recognized by certain human viruses (particularly rhinoviruses of the major type (which bind to ICAM-1). These viruses bind to human cells by virtue of this recognition, and thereby mediate viral infection.
SUBSTITUTESHEET Thus, a central step in the etiology of viral disease is the interaction between these cellular receptors and the virus.
Agents which suppress, compete with, or inhibit the ability of a virus to bind to an ICAM molecule thus have use in the treatment of viral (and particularly rhinoviral) infection.
One aspect of the present invention thus concerns the ability of the beta-subunit of human LFA-1, and its functional derivatives to interact with ICAM-1 and to thereby either prevent cell-viral attachment and viral infection, or to attenuate or diminish the severity or duration of such infection.
Of particular interest to the present invention are functional derivatives of the /J-subunit of human LFA-1 such as solubilized forms of the /J-subunit of human LFA-1, fragments of the /J-subunit of human LFA-I, etc. Such agents are preferably provided to a recipient patient as a heterodimer containing the molecule in association with a molecule of the α-subunit of a member of the CD-18 family (such as the α- subunits of LFA-1, pl50,95, or Mac-1). The above-described goal of treating viral infection may be accomplished with a single agent or with a combination of more than one agents.
For the purpose of treating viral infection, the above- described agent(s) of the present invention is to be provided to a recipient patient (for example, by intranasal means) at a dosage sufficient to permit the agent(s) to suppress, compete with, or inhibit the ability of a virus to bind to an ICAM molecule. Such a dosage shall, in general, be (for each agent provided) from 0.01 pg/kg patient weight to 1 mg/kg patient weight, although greater or lesser amounts can be employed.
For the purpose of treating viral infection, the administration of such agent(s) may be provided either "prophylactically" or "therapeutically." When provided
SUBSTITUTESHEET prophylactically, the agent(s) are provided in advance of (i.e. prior to, at, or shortly after) the time of infection but in advance of any symptoms of viral infection. The prophylactic administration of the agent(s) serves to prevent or attenuate any subsequent infection. When provided therapeutically, the agent(s) are provided at (or shortly after) the onset of a symptom of actual viral infection (such as, for example, the appearance of virally induced nasal congestion, etc. or the detection of virus in bodily fluids, or the detection of antibodies, directed against the virus, in the serum of an infected patient, etc). The therapeutic administration of the agent(s) serves to attenuate any actual infection, and thus lessen its severity or duration.
Other embodiments are within the following claims.
SUBSTITUTESHEET

Claims

Cl ai s
1. A method of treating viral infection which comprises providing to a subject in need of such treatment, an effective amount of a composition comprising the /J-subunit of human LFA- 1, or a functional derivative thereof.
2. The method of claim 1 wherein said /J-subunit of human LFA-1 is provided in association with an alpha chain of a member of the CD-18 family.
3. The method of claim 1 wherein said viral infection is a rhinoviral infection.
4. The method of claim 2 wherein said viral infection is a rhinoviral infection.
SUBSTITUTESHEET
PCT/US1990/001255 1989-03-09 1990-03-09 Method of treating viral infections using lfa-1 WO1990010652A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32123789A 1989-03-09 1989-03-09
US321,237 1989-03-09

Publications (1)

Publication Number Publication Date
WO1990010652A1 true WO1990010652A1 (en) 1990-09-20

Family

ID=23249765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/001255 WO1990010652A1 (en) 1989-03-09 1990-03-09 Method of treating viral infections using lfa-1

Country Status (4)

Country Link
EP (1) EP0462184A4 (en)
JP (1) JPH04505009A (en)
CA (1) CA2050329A1 (en)
WO (1) WO1990010652A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604647A4 (en) * 1992-07-16 1996-09-25 Icos Corp Alleviation of symptoms associated with inflammatory disease states.
US5589453A (en) * 1988-09-01 1996-12-31 Molecular Therapeutics, Inc. Human rhinovirus receptor protein (ICAM-1) that inhibits rhinovirus attachment and infectivity
US5622700A (en) * 1992-08-21 1997-04-22 Genentech, Inc. Method for treating a LFA-1-mediated disorder
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
WO2000060355A3 (en) * 1999-04-02 2001-02-08 Icos Corp Lfa-1 regulatory binding site and uses thereof
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
US6652855B1 (en) 1999-03-19 2003-11-25 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US7132395B1 (en) 1988-09-01 2006-11-07 Bayer Pharmaceuticals Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US7314938B2 (en) 2003-11-05 2008-01-01 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US7361344B2 (en) 1996-01-23 2008-04-22 Genentech, Inc. Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
US7396530B2 (en) 2004-06-09 2008-07-08 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8084047B2 (en) 2005-05-17 2011-12-27 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9085553B2 (en) 2012-07-25 2015-07-21 SARcode Bioscience, Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
US10960087B2 (en) 2007-10-19 2021-03-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006592A1 (en) * 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Cloning of lfa-1
EP0364690A3 (en) * 1988-08-23 1990-07-18 Dana Farber Cancer Institute The alpha-subunit of the mac-1 leukocyte adhesion receptor
DE68923048T2 (en) * 1988-08-23 1995-11-16 Dana Farber Cancer Inst Inc Alpha subunit of the LFA-1 leukocyte adhesion receptor.
ES2141076T3 (en) * 1988-09-01 2000-03-16 Bayer Ag HUMAN RHINOVIRUS RECEPTOR PROTEIN INHIBITING VIRUS INFECTIVITY.
ZA903223B (en) * 1989-04-28 1991-02-27 Baylor College Medicine Dissemination of hiv-1 infected cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cell, published 10 March 1989, "A Cell Adhesion Molecule, ICAM-1, is the Major Surface Receptor for Rhinoviruses", (STAUNTON), Vol. 56, pages 849-853. See pages 849, 850 and 852. *
European Journal of Immunology, Published 1987, "LFA-1 beta-chain Synthesis and Degradation in Patients with Leukocyte-adhesive Proteins Deficiency", (Dimanche), Vol. 17, pages 417-419. See pages 417 and 419. *
European Journal of Immunology, Published August 1988, "The Role of Lymphocyte Function-associated Antigen (LFA-1) in the Adherence of T Lymphocytes to B Lymphocytes", (Mazerolles), Vol. 18, pages 1229-1234. See pages 1229, 1231, and 1232. *
See also references of EP0462184A4 *
The Journal of Immunology, Published 15 August 1986, "A Human Intercellular Adhesion Molecule (ICAM-1) Distinct from LFA-1", (Rothlein), Vol. 137, pages 1270-1274. See page 1270. *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132395B1 (en) 1988-09-01 2006-11-07 Bayer Pharmaceuticals Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US5589453A (en) * 1988-09-01 1996-12-31 Molecular Therapeutics, Inc. Human rhinovirus receptor protein (ICAM-1) that inhibits rhinovirus attachment and infectivity
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
EP1069182A1 (en) * 1992-07-16 2001-01-17 Icos Corporation Alleviation of symptoms associated with inflammatory disease states, using antibodies to CD18
EP0604647A4 (en) * 1992-07-16 1996-09-25 Icos Corp Alleviation of symptoms associated with inflammatory disease states.
US5622700A (en) * 1992-08-21 1997-04-22 Genentech, Inc. Method for treating a LFA-1-mediated disorder
US7655230B2 (en) 1996-01-23 2010-02-02 Genentech, Inc. Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US7361344B2 (en) 1996-01-23 2008-04-22 Genentech, Inc. Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
US6652855B1 (en) 1999-03-19 2003-11-25 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US7364734B2 (en) 1999-03-19 2008-04-29 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
WO2000060355A3 (en) * 1999-04-02 2001-02-08 Icos Corp Lfa-1 regulatory binding site and uses thereof
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US8071617B2 (en) 2003-11-05 2011-12-06 Sarcode Bioscience Inc. Modulators of cellular adhesion
US9216174B2 (en) 2003-11-05 2015-12-22 Sarcode Bioscience Inc. Modulators of cellular adhesion
US7745460B2 (en) 2003-11-05 2010-06-29 Sarcode Corporation Modulators of cellular adhesion
US7790743B2 (en) 2003-11-05 2010-09-07 Sarcode Corporation Modulators of cellular adhesion
US7928122B2 (en) 2003-11-05 2011-04-19 Sarcode Corporation Modulators of cellular adhesion
US7989626B2 (en) 2003-11-05 2011-08-02 SAR code Corporation Modulators of cellular adhesion
US7314938B2 (en) 2003-11-05 2008-01-01 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US9248126B2 (en) 2003-11-05 2016-02-02 Sarcode Bioscience Inc. Modulators of cellular adhesion
US7396530B2 (en) 2004-06-09 2008-07-08 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US8084047B2 (en) 2005-05-17 2011-12-27 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US9051297B2 (en) 2005-05-17 2015-06-09 Sarcode Bioscience Inc. Compositions and methods for treatment
US8592450B2 (en) 2005-05-17 2013-11-26 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US8758776B2 (en) 2005-05-17 2014-06-24 Sarcode Bioscience Inc. Compositions and methods for treatment
US8771715B2 (en) 2005-05-17 2014-07-08 Sarcode Bioscience Inc. Compositions and methods for treatment
US10188641B2 (en) 2005-05-17 2019-01-29 Sarcode Bioscience Inc. Compositions and methods for treatment
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US9045458B2 (en) 2005-05-17 2015-06-02 Sarcode Bioscience Inc. Compositions and methods for treatment
US9045457B2 (en) 2005-05-17 2015-06-02 Sarcode Bioscience Inc. Compositions and methods for treatment
US10960087B2 (en) 2007-10-19 2021-03-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
US8871935B2 (en) 2008-04-15 2014-10-28 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8367701B2 (en) 2008-04-15 2013-02-05 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US11028077B2 (en) 2008-04-15 2021-06-08 Novartis Pharmaceuticals Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8927574B2 (en) 2009-10-21 2015-01-06 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9353088B2 (en) 2009-10-21 2016-05-31 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9890141B2 (en) 2009-10-21 2018-02-13 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9085553B2 (en) 2012-07-25 2015-07-21 SARcode Bioscience, Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
US10214517B2 (en) 2012-07-25 2019-02-26 Sarcode Bioscience Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
US10906892B2 (en) 2012-07-25 2021-02-02 Novartis Pharmaceuticals Corporation LFA-1 inhibitor and methods of preparation and polymorph thereof

Also Published As

Publication number Publication date
EP0462184A4 (en) 1992-01-08
JPH04505009A (en) 1992-09-03
EP0462184A1 (en) 1991-12-27
CA2050329A1 (en) 1990-09-10

Similar Documents

Publication Publication Date Title
US5739032A (en) Cloning LFA-1
WO1990010652A1 (en) Method of treating viral infections using lfa-1
Sano et al. Protocadherins: a large family of cadherin‐related molecules in central nervous system.
US5773578A (en) Proteins produced by human lymphocytes, DNA sequence encoding these proteins and their pharmaceutical and biological use
Medof et al. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.
Allen et al. Isolation and expression of functional high-affinity Fc receptor complementary DNAs
CA2143491C (en) A novel peptide related to human programmed cell death and dna encoding it
US6380360B1 (en) Polycystic kidney disease 1 gene and uses thereof
CA1341293C (en) Alpha-subunit of the mac-1 leukocyte adhesion receptor
EP0394302B1 (en) DNA ENCODING IgE RECEPTOR ALPHA-SUBUNIT OR FRAGMENT THEREOF
EP0362526B1 (en) The Alpha-subunit of the LFA-1 leukocyte adhesion receptor
EP0387668A1 (en) Intercellular adhesion molecule - 2 and its binding ligands
CA2293735A1 (en) Lag-3 splice variants
DiSanto et al. The human Lyt‐3 molecule requires CD8 for cell surface expression.
US5652210A (en) Soluble splice variant of the Fas (APO-1) antigen, FasΔTM
Reiser et al. Cloning and expression of a cDNA for the T-cell-activating protein TAP.
US5169835A (en) Pregancy specific proteins applications
US20020110864A1 (en) Polypeptide and DNAs encoding it
EP0462205A4 (en) Leukocyte adhesion receptors
AU645965C (en) Pregnancy specific proteins applications
WO1995004756A1 (en) Complement inhibitor proteins of non-human primates
IL90488A (en) Ifn-beta2/il-6 receptor its preparation and pharmaceutical compositions containing it
NZ244853A (en) Antibodies and fragments to icam-1, pharmaceutical composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2050329

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990904579

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990904579

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990904579

Country of ref document: EP

ENP Entry into the national phase

Ref country code: CA

Ref document number: 2050329

Kind code of ref document: A

Format of ref document f/p: F